Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Mounjaro in the UK — patient guide
Mounjaro is the brand name for tirzepatide — the dual GLP-1 / GIP receptor agonist licensed in the UK for type 2 diabetes and weight management. This guide covers the KwikPen, NICE TA1026 eligibility, the February 2026 falsified 15 mg KwikPen alert, and lawful access.
What Mounjaro is
Mounjaro is the brand name Eli Lilly uses for tirzepatide. It is a dual agonist — activating both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. In clinical trials this dual mechanism produces larger weight-loss effects than single-agonist GLP-1 therapies. In the UK Mounjaro is licensed for type 2 diabetes and (under NICE TA1026) for weight management in specific patient groups.
The KwikPen
Mounjaro is supplied as a pre-filled, multi-dose KwikPen (or, in some routes, as single-dose vials for diabetes treatment). The KwikPen has the Eli Lilly branding, an identifiable dial mechanism, and the dose strength printed on the label.
Standard dose strengths and titration:
- Weeks 1–4: 2.5 mg weekly (starter dose, not therapeutic)
- Weeks 5+: 5 mg weekly (first maintenance step)
- Escalate to 7.5 mg, 10 mg, 12.5 mg, or 15 mg at four-week intervals as tolerated.
Many patients respond well at 5 mg or 10 mg without needing the higher strengths. Titration is the most important tool for managing GI side effects.
NHS access — NICE TA1026
NICE technology appraisal TA1026 recommends tirzepatide on the NHS for weight management. Headline criteria:
- BMI of at least 35 kg/m² with at least one weight-related medical condition.
- Lower BMI thresholds apply for some ethnic backgrounds where cardiometabolic risk emerges at lower BMI.
- Use within a specialist weight-management service initially; primary-care pathways are being phased in.
NHS roll-out is phased and access varies by ICB / health-board. Patients should expect a clinical assessment with mental-health screening and contraindication review.
February 2026 falsified KwikPen alert
In February 2026 the MHRA issued a public-health alert about falsified Mounjaro 15 mg KwikPens reaching UK patients via unlicensed supply routes. The falsified products appeared in supplies obtained outside the regulated UK supply chain (i.e. not from a GPhC-registered pharmacy against a UK prescription). See fake Mounjaro pens for the specific identifiers and what to do if you may have received one.
Lawful private access
A GMC-registered prescriber can lawfully prescribe Mounjaro on a private prescription where clinically appropriate, with the medicine dispensed by a GPhC-registered (or PSNI) pharmacy. A competent private route always includes a real clinical assessment, a named prescriber, and follow-up. See peptide clinics and UK law for the registration checks.
Side-effect overview
The most common side effects are gastrointestinal — nausea, decreased appetite, diarrhoea, constipation, and vomiting — and are largely dose-dependent. Less common but more serious are gallbladder disease, pancreatitis, and (in T2DM patients) risk of hypoglycaemia in combination with insulin or sulfonylureas. Detailed view at Mounjaro side effects (UK).
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Mounjaro 15mg in stock — no consultation needed”
Direct-to-public POM advertising AND supply without a prescription. Both HMR 2012 breaches. The Feb 2026 falsified KwikPen alert came from supplies obtained this way.
“Compounded tirzepatide — half the price”
‘Compounded’ marketed on price is not the UK ‘specials’ framework. Mass-market compounded tirzepatide is an MHRA enforcement target.
“Generic Mounjaro KwikPen”
There is no generic Mounjaro. ‘Generic Mounjaro’ is either a falsified product or an unlicensed-substance supply.
“Skip the waiting list — guaranteed Mounjaro”
‘Skip the waiting list’ usually means skipping the clinical assessment that makes prescribing lawful.
“Doctor will prescribe outside the BMI criteria for £X extra”
Paid override of clinical criteria is not lawful private prescribing. GMC standards apply regardless of payment.
Sources & further reading
- NICE TA1026 — tirzepatide for weight management — nice.org.uk
- MHRA — gov.uk
- MHRA Drug Safety Update — gov.uk
- Yellow Card — report side effects and counterfeits — yellowcard.mhra.gov.uk
- Report a problem with a medicine or medical device — gov.uk
- NHS — obesity treatment — nhs.uk